ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And Function) is a Phase 4, Prospective, Multi-center, Single-Arm Study to assess the effect of early and rapid treprostinil therapy to reduce mean pulmonary artery pressure (mPAP, improve right ventricular (RV) function, and reverse RV remodeling, in patients with pulmonary arterial hypertension (PAH). Estimated enrolment is 50 persons, in 25 sites in the US. The sponsor is United Therapeutics.
Source: Pulmonary Vascular Research Institute (PVRI) website, News section, May 24, 2023, at this link
For full details of the study consult the dedicated page on the ClinicalTrials.gov website
Disclaimer
While every possible effort will be taken to ensure that the Pulmonary Hypertension Knowledge Sharing Platform content is accurate and up-to-date, it may still include opinions of experts that are the best knowledge at the time of publication but may now be outdated, and materials that are otherwise inaccurate or incomplete. We invite visitors to consult with their health care professionals before making any decisions based upon them.